VB10.16
Human papillomavirus type 16 (HPV16)-positive cancers
Phase 2Active
Key Facts
Indication
Human papillomavirus type 16 (HPV16)-positive cancers
Phase
Phase 2
Status
Active
Company
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharma company founded in 2006, leveraging its proprietary Vaccibody™ platform to develop targeted immunotherapies for cancer and autoimmune diseases. Its lead candidate, VB10.16, is a potentially first-in-class, off-the-shelf therapeutic for HPV16-positive cancers. The company's strategy focuses on accelerating its pipeline, expanding its platform into new therapeutic areas like autoimmunity, and forming value-creating strategic partnerships with industry leaders.
View full company profile